Noteworthy, PARP3 seems to be overexpressed in tumors that benefit from trabectedin treatment (i.e., L‐sarcomas and tumors with somatic location), while PARP1 expression is higher in sarcomas with lower activity of trabectedin (non‐L‐sarcomas and tumors with visceral location). The gene discussed is PARP1; the disease is sarcoma.